C
0.094
0.00 (2.07%)
| 前收盘价格 | 0.092 |
| 收盘价格 | 0.092 |
| 成交量 | 4,500,385 |
| 平均成交量 (3个月) | 15,417,863 |
| 市值 | 7,023,986 |
| 股市价格/股市净资产 (P/B) | 0.250 |
| 52周波幅 | |
| 利润日期 | 31 Mar 2025 - 4 Apr 2025 |
| 稀释每股收益 (EPS TTM) | -1,943.50 |
| 总债务/股东权益 (D/E MRQ) | 5.28% |
| 流动比率 (MRQ) | 3.43 |
| 营业现金流 (OCF TTM) | -17.11 M |
| 杠杆自由现金流 (LFCF TTM) | -13.27 M |
| 资产报酬率 (ROA TTM) | -179.08% |
| 股东权益报酬率 (ROE TTM) | -1,703.39% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | CNS Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.38 |
|
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.40% |
| 机构持股比例 | 2.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Barrett & Company, Inc. | 31 Mar 2025 | 100 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合